Moreover, TXNDC17 promotes tumor resistance to paclitaxel in ovarian cancer by regulating BECN1‐mediated autophagy, and high TXNDC17 expression has been confirmed to be associated with poor prognosis in patients with ovarian cancer [31]. This evidence concerns the gene TXNDC17 and ovarian carcinoma.